Gane E. Safety and Efficacy at 1 year after Switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use. PS-156.
Tuberculosevaccin versterkt afweerrespons tegen malaria
mrt 2019 | Bacteriële infecties, Parasitaire infecties, Vaccinatie